PMV Pharmaceuticals, Inc. 8K

PMV Pharmaceuticals announced second quarter 2026 results, completion of key Phase 2 PYNNACLE trial enrollment for rezatapopt in ovarian cancer, an NDA submission planned for Q1 2027, and cash runway projected through Q2 2027.

On August 14, 2026, PMV Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting completion of enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of its registrational PYNNACLE trial of rezatapopt, reaffirming plans to submit a New Drug Application for rezatapopt for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation in the first quarter of 2027, and disclosing that it held $79.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects will fund operations through the second quarter of 2027, alongside a reduced quarterly net loss driven mainly by lower R&D and G&A expenses.

Filing Facts

CIK

1699382

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-350445

Alert Tier

7